Xia Jiachen, Quan Hui, Huang Yuying, Zhang Zhecheng, Zhang Yuehua, Lu Bing
College of Chemistry and Chemical Engineering, Nantong University, No.9 Seyuan Road, Chongchuan District, Nantong, Jiangsu 226019, P. R. China.
ACS Macro Lett. 2024 May 21;13(5):489-494. doi: 10.1021/acsmacrolett.4c00031. Epub 2024 Apr 12.
Synchronously improving the photothermal conversion efficiency and photodynamic activity of organic small molecule photosensitizers is crucial for their further wide application in cancer treatment. Recently, the emerging A-D-A photosensitizer-based phototherapy systems have attracted great interest due to their plentiful inherent merits. Herein, we propose a design strategy for A-D-A photosensitizers with synchronously enhanced photothermal conversion and reactive oxygen species (ROS) generation efficiencies. Side chain programming is carried out to design three A-D-A photosensitizers (IDT-H, IDT-Br, IDT-I) containing hexyl, bromohexyl, and iodohexyl side chains, respectively. Theoretical calculations confirm that a bulky iodine atom could weaken the intermolecular π-π stacking and enhance spin-orbit coupling constants of IDT-I. These molecular mechanisms enable IDT-I nanoparticles (NPs) to exhibit 2.4-fold and 1.7-fold higher ROS generation efficiency than that of IDT-H NPs and IDT-Br NPs, respectively, as well as the highest photothermal conversion efficiency. Both the experimental results and verify that IDT-I NPs are perfectly qualified for the mission of photothermal and photodynamic synergistic therapy. Therefore, in this contribution, we provide a promising perspective for the design of A-D-A photosensitizers with simultaneously improved photothermal and photodynamic therapy ability.
同步提高有机小分子光敏剂的光热转换效率和光动力活性对于其在癌症治疗中的进一步广泛应用至关重要。最近,新兴的基于A-D-A光敏剂的光疗系统因其丰富的固有优点而引起了极大的兴趣。在此,我们提出了一种设计策略,用于设计具有同步增强的光热转换和活性氧(ROS)生成效率的A-D-A光敏剂。通过侧链编程设计了三种分别含有己基、溴己基和碘己基侧链的A-D-A光敏剂(IDT-H、IDT-Br、IDT-I)。理论计算证实,庞大的碘原子可以减弱分子间的π-π堆积并增强IDT-I的自旋轨道耦合常数。这些分子机制使IDT-I纳米颗粒(NPs)的ROS生成效率分别比IDT-H NPs和IDT-Br NPs高2.4倍和1.7倍,同时具有最高的光热转换效率。实验结果均证实IDT-I NPs完全胜任光热和光动力协同治疗的任务。因此,在本研究中,我们为设计同时具有改善的光热和光动力治疗能力的A-D-A光敏剂提供了一个有前景的视角。